(19)
(11) EP 4 798 592 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24804671.6

(22) Date of filing: 24.10.2024
(51) International Patent Classification (IPC): 
C07D 498/04(2006.01)
A61P 17/06(2006.01)
A61P 37/00(2006.01)
C07D 519/00(2006.01)
A61P 29/00(2006.01)
A61K 31/553(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 519/00; C07D 498/04; A61P 17/06; A61P 29/00; A61P 37/00
(86) International application number:
PCT/US2024/052804
(87) International publication number:
WO 2025/090758 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.10.2023 US 202363593599 P
26.04.2024 US 202463639359 P

(71) Applicant: Eli Lilly and Company
Indianapolis, IN 46285 (US)

(72) Inventors:
  • CARSON, Cheryl Ann
    Indianapolis, Indiana 46206-6288 (US)
  • CLARKE, Christian Alexander
    Indianapolis, Indiana 46206-6288 (US)
  • DORSEY, Frank Charles
    Indianapolis, Indiana 46206-6288 (US)
  • GERNERT, Douglas L.
    Indianapolis, Indiana 46206-6288 (US)
  • HOLLOWAY, William Glen
    Indianapolis, Indiana 46206-6288 (US)
  • MCMILLEN, William Thomas
    Indianapolis, Indiana 46206-6288 (US)
  • NIKOLAOU, Christodoulos
    Indianapolis, Indiana 46206-6288 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) AHR AGONISTS